A new study presented this week at The Liver Meeting — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication.

Read the original:
HCV patients treated with DAA therapy not at increased risk of developing liver cancer, study finds

Scroll to Top